Crystallization products of risedronate with carbohydrates and their substituted derivatives

Molecules

Volumn 16, Issue 5, 2011, Pages 3740-3760

  Kos, Jiri ^a   Pentakova, Monika ^a   Oktabec, Zbynek ^a,b,c   Krejcik, Lukas ^a,b   Mandelova, Zuzana ^a,b   Harokova, Pavla ^a   Hruskova, Jana ^a   Pekarek, Tomas ^b   Dammer, Ondrej ^b   Tkadlecova, Marcela ^b   Havlicek, Jaroslav ^b   Vinsova, Jarmila ^c   Kral, Vladimir ^b,d   Dohnal, Jiri ^a,b   Jampílek, Josef ^a,b  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b Zentiva Prague   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^d INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

CP MAS NMR; DSC; FT NIR; FT Raman; Phenyl D galactopyranoside; Polymorph P; Risedronate; XRPD

Indexed keywords

CARBOHYDRATE; DRUG DERIVATIVE; ETIDRONIC ACID; GALACTOSIDE; PHENYL D GALACTOPYRANOSIDE; PHENYL-D-GALACTOPYRANOSIDE; RISEDRONIC ACID;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAMAN SPECTROMETRY; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBOHYDRATES; CRYSTALLIZATION; ETIDRONIC ACID; GALACTOSIDES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 79957617907     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16053740     Document Type: Article

References (32)

1. Pharmaterials Ltd. Available online: http://www.pharmaterials.co.uk/co- crystals.html. (accessed on 11 January 2011).
2. Tiekink, E.R.T., Vittal, J., Eds.; Frontiers in Crystal Engineering. Wiley-VCH: Wienheim, Germany, 2005.
3. Braga, D., Grepioni, F., Eds. Making crystals by Design: Methods, Techniques and Applications; Wiley-VCH: Wienheim, Germany 2006.
4. Ebetino, F.H.; Francis, M.D.; Rogers, M.J.; Russell, R.G.G. Mechanisms of action of etidronate and other bisphosphonates. Rev. Contemp. Pharmacother. 1998, 9, 233-243. (Pubitemid 28297549)
5. Sato, M.; Grasser, W.; Endo, N.; Akins, R.; Simmons, H.; Thompson, D.D.; Golub, E.; Rodan, G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991, 88, 2095-2105.
6. Carano, A.; Teitelbaum, S.L.; Konsek, J.D.; Schlesinger, P.H.; Blair, H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 1990, 85, 456-461. (Pubitemid 20070052)
7. Hughes, D.E.; Wright, K.R.; Uy, H.L.; Sasaki, A.; Yoneda, T.; Roodman, G.D.; Mundy, G.R.; Boyce, B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995, 10, 1478-1487.
8. Selander, K.S.; Monkkonen, J.; Karhukorpi, E.K.; Harkonen, P.; Hannuniemi, R.; Vaananen, H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 1996, 50, 1127-1138. (Pubitemid 26384851)
9. Ito, M.; Amizuka, N.; Nakajima, T.; Ozawa, H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 1999, 25, 447-452. (Pubitemid 29424238)
10. Reszka, A.A.; Halasy-Nagy, J.M.; Masarachia, P.J.; Rodan, G.A. Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 1999, 274, 34967-34973. (Pubitemid 129509546)
11. Rogers, M.J.; Xiong, X.; Brown, R.J.; Watts, D.J.; Russell, R.G.; Bayless, A.V.; Ebetino, F.H. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol. Pharmacol. 1995, 47, 398-402.
12. Rogers, M.J.; Gordon, S.; Benford, H.L.; Coxon, F.P.; Luckman, S.P.; Monkkonen, J.; Frith, J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88, 2961-2978. (Pubitemid 30413179)
13. van Beek, E.R.; Lowik, C.W.; Ebetino, F.H.; Papapoulos, S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone 1998, 23, 437-442. (Pubitemid 28470613)
14. MedicineNet. Available online: http://www.medicinenet.com/risedronate/ article.htm (accessed on 11 January 2011).
15. TM. Available online: http://osteoporosis.emedtv.com/ (accessed on 11 January 2011).
16. Ezra, A.; Golomb, G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Del. Rev. 2000, 42, 175-195. (Pubitemid 30645777)
17. Kerns, E.H.; Li, D. Drug-like Properties: Concept, Structure Design and Methods; Elsevier: San Diego, CA, USA, 2008.
18. Luypaert, J.; Massart, D.L.; Vander-Heyden, Y. Near-infrared spectroscopy applications in pharmaceutical analysis. Talanta 2007, 72, 865-883. (Pubitemid 46635544)
19. ® 11), Stamford, CT, USA, 14-19 June 2009.
20. Jampilek, J.; Oktabec, Z.; Rezacova, A.; Placek, L.; Kos, J.; Havelkova, L.; Dohnal, J.; Kral, V. Preparation and properties of new co-crystals of ibandronate. In Proceedings of the 13th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-13), 1-30 November 2009.
21. Jampilek, J.; Kos, J.; Oktabec, Z.; Mandelova, Z.; Pekarek, T.; Tkadlecova, M.; Havlicek, J.; Dohnal, J.; Kral V. Co-crystal screening study of risedronate and unsubstituted hexoses. In proceedings of the 14th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-14), 1-30 November 2010.
22. Oktabec, Z.; Kos, J.; Havelkova, L.; Mandelova, Z.; Pekarek, T.; Rezacova, A.; Placek, L.; Tkadlecova, M.; Havlicek, J.; Dohnal, J.; Jampilek, J. Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives. Molecules 2010, 15, 8973-8987.
23. Richter, J.; Jirman, J. Crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1- bisphosphonic acid. Zentiva, a.s. U.S. Patent 7,276,604, 2 October 2007.
24. Cazer, F.D.; Perry, G.E.; Billings, D.M.; Redman-Furey, N.L. Selective crystallization of 3-pyridyl-1-hydroxy-ethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate. Warner Chilcott Company, LLC. EP1252170 A2, 1 February 2001.
25. Aronhime, J.; Lifshitz-Liron, R.; Kovalevski-Ishai, E.; Lidor-Hadas, R. Novel polymorphs and pseudopoly-morphs of risedronate sodium. TEVA Pharmaceutical Industries, Ltd. CA2480764 A1, 23 October 2003.
26. Aronhime, J.; Lifshitz-Liron, R.; Kovalevski-Ishai, E.; Lidor-Hadas, R. Novel polymorphs and pseudopolymorphs of risedronate sodium. TEVA Pharmaceutical Industries, Ltd. WO 03/086355 A1, 23 October 2003.
27. Redman-Furey, N.L.; Ficka, M.; Bigalow-Kern, A.; Cambron, R.T.; Lubey, G.; Lester, C.; Vaughn, D. Structural and analytical characterization of three hydrates and an anhydrate form. J. Pharm. Sci. 2005, 94, 893-911.
28. Gossman, W.L.; Wilson, S.R.; Oldfield, E. Three hydrates of the isphosphonates risedronate, consisting of one molecular and two ionic structures. Acta Cryst. C 2003, 59, m33-m36.
29. Bruning, J.; Petereit, A.C.; Alig, E.; Bolte, M.; Dressman, J.B.; Schmidt, M.U. Characterization of a new solvate of risedronate. J. Pharm. Sci. 2011, 100, 863-873.
30. Avogadro: An Open-source Molecular Builder and Visualization Tool, Version 1.0.1. Available online: http://avogadro.openmolecules.net/ (accessed on 28 April 2010).
31. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Montgomery, Jr., J.A.; Vreven, T.; Kudin, K.N.; Burant, J.C.; Millam, J.M.; Iyengar, S.S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G.A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J.E.; Hratchian, H.P.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Ochterski, J.W.; Ayala, P.Y.; Morokuma, K.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Zakrzewski, V.G.; Dapprich, S.; Daniels, A.D.; Strain, M.C.; Farkas, O.; Malick, D.K.; Rabuck, A.D.; Raghavachari, K.; Foresman, J.B.; Ortiz, J.V.; Cui, Q.; Baboul, A.G.; Clifford, S.; Cioslowski, J.; Stefanov, B.B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R.L.; Fox, D.J.; Keith, T.; Al-Laham, M.A.; Peng, C.Y.; Nanayakkara, A.; Challacombe, M.; Gill, P.M.W.; Johnson, B.; Chen, W.; Wong, M.W.; Gonzalez, C.; Pople, J.A. Gaussian 03, Revision C.02; Gaussian, Inc.: Wallingford, CT, USA, 2004.
32. Case, D.A.; Darden, T.A.; Cheatham, III, T.E.; Simmerling, C.L.; Wang, J.; Duke, R.E.; Luo, R.; Merz, K.M.; Pearlman, D.A.; Crowley, M.; Walker, R.C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K.F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D.H.; Schafmeister, C.; Ross, W.S.; Kollman, P.A. AMBER 9. University of California: San Francisco, CA, USA, 2006.